Gilead Sciences’s most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $62.50 short put and a strike $57.50 long put offers a potential 13.64% return on risk over the next 26 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $62.50 by expiration. The full premium credit of $0.60 would be kept by the premium seller. The risk of $4.40 would be incurred if the stock dropped below the $57.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 61.82 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Actelion’s Opsumit Cleared in the U.S.
Mon, 21 Oct 2013 20:20:02 GMT
Zacks – Actelion Ltd recently received FDA approval for Opsumit 10 mg once daily for the treatment of pulmonary arterial hypertension (PAH WHO Group I).
Gilead and Johnson & Johnson Face the FDA
Mon, 21 Oct 2013 18:34:05 GMT
Motley Fool – Both Gilead and Johnson & Johnson have advisory committee meetings this week for their hepatitis C drugs that will be used in combination with injected drugs from Merck and Roche. Neither looks like much …
Eventide Gilead Fund Ranked Best Performing Mutual Fund by The New York Times for the Five-Year Period Ending September 30, 2013 Based on Total Returns
Mon, 21 Oct 2013 12:45:00 GMT
Marketwired – The Eventide Gilead Fund , a mutual fund practicing values-based investing, was ranked as the best performing mutual fund with over $50 Million in assets by The New York Times for the five-year period …
Can Amgen Grow Faster Than Gilead Sciences and Teva Pharmaceutical?
Sun, 20 Oct 2013 16:46:20 GMT
Motley Fool – Amgen is seen as the quiet dividend-payer of the biotech space, but Amgen earnings could give Teva Pharmaceutical and Gilead Sciences a run for their money.
Fri, 18 Oct 2013 11:32:00 GMT
Forbes – Actual bubble, not to be confused with the metaphorical bubble discussed at left. (Photo credit: Wikipedia) For me, one glance was all it took. Looking at my colleague’s computer from across the room, I could see that this pre-IPO company’s lead oncology asset — presumably the driving force behind this white-hot offering […]
Also on Market Tamer…
Follow Us on Facebook